STOCK TITAN

If You Invested in Innoviva, Inc. (INVA)

Healthcare · Biotechnology · NASDAQ
Looking for the current price? See the INVA quote & overview
$1,000 invested 1 Year Ago
$865
-13.5% price return
-13.5% with dividends reinvested
Bought on Nov 19, 2025 at $21.27 split-adjusted
$1,000 invested 5 Years Ago
$1,079
+7.9% price return 1.5% CAGR
+7.9% with dividends reinvested
Bought on Nov 19, 2021 at $17.05 split-adjusted

What $1,000 or $10,000 in INVA Would Be Worth Now

Real historical value by amount invested and how long ago
If you invested 1 year ago 5 years ago 10 years ago Since Nov 20, 2015
$1,000 $865 -13% $1,079 +8% $1,685 +68% $2,063 +106%
$10,000 $8,651 -13% $10,792 +8% $16,850 +68% $20,628 +106%

Based on real historical closing prices adjusted for stock splits, without dividends, through 2026-11-18. Figures with dividends reinvest each cash dividend at the previous close less the dividend, before taxes. Past performance does not guarantee future results.

Custom Calculation

Choose your own date and amount for INVA

$1,000 Investment Over Time

INVA vs S&P 500

Year-by-Year Returns

INVA annual performance
Year Start Price End Price Annual Return Cumulative
2015Nov 20 to Dec 31 $8.92 $10.54 +18.2% +18.2%
2016 $10.54 $10.70 +1.5% +20.0%
2017 $10.70 $14.19 +32.6% +59.1%
2018 $14.19 $17.45 +23.0% +95.6%
2019 $17.45 $14.16 -18.9% +58.7%
2020 $14.16 $12.39 -12.5% +38.9%
2021 $12.39 $17.25 +39.2% +93.4%
2022 $17.25 $13.25 -23.2% +48.5%
2023 $13.25 $16.04 +21.1% +79.8%
2024 $16.04 $17.35 +8.2% +94.5%
2025 $17.35 $19.99 +15.2% +124.1%
2026Dec 31, 2025 to Nov 18 $19.99 $18.40 -8.0% +106.3%

About Innoviva, Inc.

Healthcare · NASDAQ

Innoviva, Inc. (NASDAQ: INVA) is a diversified healthcare holding company with a focus on pharmaceutical preparation manufacturing and commercial-stage therapeutics. According to company disclosures, Innoviva combines a core royalties portfolio, a critical care and infectious disease platform operated through Innoviva Specialty Therapeutics, and a portfolio of strategic investments in healthcare assets. The company’s common stock is listed on the NASDAQ Global Select Market under the symbol INVA.

Innoviva’s royalties portfolio centers on respiratory assets partnered with Glaxo Group Limited (GSK). Innoviva is entitled to receive royalties from GSK on sales of RELVAR®/BREO® ELLIPTA® and ANORO® ELLIPTA®. These royalty streams provide an ongoing revenue source that complements Innoviva’s operating businesses and investment activities.

Innoviva Specialty Therapeutics: Critical Care and Infectious Disease

Through its subsidiary Innoviva Specialty Therapeutics (IST), Innoviva is active in the development and commercialization of therapies for serious infections and critical care conditions. IST’s commercial portfolio, as described in company news releases, includes multiple FDA-approved medicines:

  • GIAPREZA® (angiotensin II), through the La Jolla Pharmaceutical Company affiliate, approved to increase blood pressure in adults with septic or other distributive shock.
  • XERAVA® (eravacycline), through La Jolla, approved for the treatment of complicated intra-abdominal infections in adults.
  • XACDURO® (sulbactam for injection; durlobactam for injection), through Entasis Therapeutics Inc., co-packaged for intravenous use and approved for adults with hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia caused by susceptible strains of Acinetobacter baumannii-calcoaceticus complex.
  • ZEVTERA® (ceftobiprole medocaril sodium for injection), an advanced-generation cephalosporin antibiotic approved in the U.S. for adult patients with Staphylococcus aureus bloodstream infections (bacteremia), including right-sided infective endocarditis, adult patients with acute bacterial skin and skin structure infections (ABSSSI), and adult and pediatric patients (3 months to less than 18 years old) with community-acquired bacterial pneumonia (CABP).

IST also develops and presents clinical, pharmacokinetic-pharmacodynamic, and microbiologic data across this portfolio, reflecting a focus on serious bacterial infections, drug-resistant pathogens, and critical care settings.

Zoliflodacin / NUZOLVENCE® and Gonorrhea Treatment

A key asset associated with Innoviva’s infectious disease platform is zoliflodacin, a first-in-class, single-dose, oral antibiotic from the spiropyrimidinetrione class. It has been developed as a treatment for uncomplicated urogenital gonorrhea, including infections caused by strains resistant to current first-line therapies. In collaboration with the Global Antibiotic Research & Development Partnership (GARDP), Innoviva Specialty Therapeutics supported a pivotal Phase 3, multinational, randomized, controlled trial that demonstrated non-inferiority of a single 3 g oral dose of zoliflodacin compared to ceftriaxone plus azithromycin in uncomplicated urogenital gonorrhea.

Innoviva reports that the U.S. Food and Drug Administration (FDA) granted zoliflodacin Qualified Infectious Disease Product (QIDP) designation, allowing Priority Review and extended market exclusivity. Subsequent disclosures describe FDA acceptance of a New Drug Application and assignment of a Prescription Drug User Fee Act (PDUFA) target action date. In later communications, Innoviva Specialty Therapeutics announced FDA approval of NUZOLVENCE® (zoliflodacin) for oral suspension as a first-in-class, single-dose oral medication for adults and pediatric patients 12 years and older weighing at least 35 kg with uncomplicated urogenital gonorrhea.

NUZOLVENCE is described as a bacterial type II topoisomerase inhibitor with a mechanism of action distinct from currently approved antibiotics and with demonstrated activity against drug-resistant Neisseria gonorrhoeae. Company materials also summarize key safety information, including contraindications, embryo-fetal toxicity warnings, potential testicular toxicity and fertility risks based on animal data, hypersensitivity reactions, Clostridioides difficile infection risk, and common adverse reactions such as headache, dizziness, nausea, and diarrhea.

Therapeutic Focus and Disease Areas

Across its specialty therapeutics platform, Innoviva concentrates on serious infectious diseases and critical care indications. Its marketed and pipeline assets address:

  • Drug-resistant gram-negative infections, including HABP/VABP due to susceptible Acinetobacter baumannii-calcoaceticus complex (XACDURO).
  • Gram-positive infections such as MRSA-related Staphylococcus aureus bacteremia, ABSSSI, and CABP (ZEVTERA).
  • Complicated intra-abdominal infections in adults (XERAVA).
  • Hemodynamic support in septic or other distributive shock (GIAPREZA).
  • Sexually transmitted infections, specifically uncomplicated gonorrhea, including drug-resistant strains (zoliflodacin/NUZOLVENCE).

Innoviva Specialty Therapeutics frequently presents clinical and pharmacologic data at major infectious disease meetings such as IDWeek, highlighting subgroup analyses, microbiologic surveillance, and PK-PD modeling for agents like zoliflodacin, ceftobiprole, sulbactam-durlobactam, and eravacycline.

Strategic Investments and Capital Allocation

Beyond royalties and marketed products, Innoviva maintains a portfolio of strategic healthcare investments held through various subsidiaries. Company reports reference investments in organizations developing therapies and technologies in areas such as infectious disease and neurotechnology. Innoviva also discloses activities such as term loans to development-stage companies and equity investments in private and public healthcare businesses.

Innoviva’s financial communications describe the company’s use of capital for share repurchase programs, debt management, and acquisitions of therapeutic assets and platforms, such as the acquisition of a long-acting oral drug delivery platform and related assets from Lyndra Therapeutics, Inc. These activities are presented as part of a broader capital allocation approach within its diversified holding company structure.

Stock Listing, Sector, and Regulatory Reporting

Innoviva’s common stock trades on the NASDAQ Global Select Market under the ticker INVA. The company is classified in the pharmaceutical preparation manufacturing industry within the broader manufacturing sector. Innoviva files periodic and current reports with the U.S. Securities and Exchange Commission (SEC), including Form 8-K filings that furnish quarterly earnings press releases and other material information.

Market Cap
$1.3B
Current Price
$18.40
EPS (FY2025)
$3.30
Revenue (FY2025)
$411.3M
Net Margin (FY2025)
65.9%
View full INVA overview

Frequently Asked Questions

Innoviva, Inc. investment returns

How much would $1,000 invested in Innoviva, Inc. be worth today?

If you invested $1,000 in Innoviva, Inc. (INVA) 10 years ago on 2016-11-21, your investment would be worth $1,685 as of 2026-11-18, a +68.5% price return without dividends, growing at a compounded rate of 5.4% per year (CAGR).

Has Innoviva, Inc. outperformed the S&P 500?

Over the past 10 years, INVA returned +68.5% compared to +231.7% for the S&P 500, underperforming the benchmark by 163.2 percentage points.

What is Innoviva, Inc.'s average annual return?

The compound annual growth rate (CAGR) of INVA’s share price over the past 10 years is 5.4%, without dividends. Individual years vary a great deal, and INVA’s best recent full year was 2021 (+39.2%) while the worst was 2022 (-23.2%).

For informational and educational purposes only, not investment advice.